pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›leronlimab
drug · antibody
save

leronlimab

Phase 2updated 3mo ago
by $CYDY CytoDyn Inc.🔗 ChEMBL
Phase 2
community read0 votes

Antibody drug with a maximum clinical stage of Phase 3 (across all indications), with 7 investigational indications.

indications

indications
NSCLCMelanoma

targets

C-C chemokine receptor type 5

all catalysts(0)

nothing on the calendar yet

Trials studying leronlimab

  • phase2The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Trial (CLOVER)active not recruitingn=66
  • —An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)available
  • phase2Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumorscompletedn=16
  • phase2Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19completedn=484
  • phase2Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBCterminatedn=10
  • —A Compassionate Use Study of Leronlimab in Breast Cancerno longer available
  • phase2Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19completedn=56

News(0)

no news has mentioned this drug yet

generic
leronlimab
MOA
C-C chemokine receptor type 5 antagonist
indication
Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH)
phase
phase_2
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 9m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?